| Ytd | 38.07% | |
| 1y | 189.85% |
| Open | 12.96 | Prev Close | 13.04 | Low | 12.80 | High | 13.44 | Mkt Cap | 1.26B |
| Vol | 2.02M | Avg Vol | 4.16M | EPS | -3.15 | P/E | N/A | Forward P/E | -7.38 |
| Beta | 0.94 | Short Ratio | 9.39 | Inst. Own | 105.77% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 13.62 | 200-d Avg | 8.98 | 1yr Est | 19.50 |
REPL News
Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency
New class action for Replimune (REPL) urges investors to seek recovery for alleged securities fraud
If you purchased or acquired Replimune securities between October 20, 2025 and April 10, 2026 and wo
Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the develop
ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help
NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogni
Important Information Regarding Section 20(a) Individual Liability Claims: CEO Sushil Patel and CFO
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been
Investors allege Replimune Group, Inc. built its RP1 regulatory strategy around single-arm trial des
If you purchased or acquired Replimune securities between October 20, 2025 and April 10, 2026 and w
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has
Investors allege Replimune Group, Inc. supported its RP1 biologics license resubmission with data fr
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Replimune Group, Inc.,
San Diego, California--(Newsfile Corp. - September 28, 2026) - Shareholder rights law firm Robbins L
NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogn
Institutional holders of Replimune Group, Inc. (NASDAQ: REPL) may wish to evaluate lead plaintiff op
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has bee
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogn
Investors allege Replimune Group, Inc. told the market its RP1 resubmission was a complete response
Disclosure Under Scrutiny: Replimune's SEC filings warned generally that RP1 might not win approval,
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has
JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raise
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst
The aggregate gross proceeds from the offering are expected to be approximately $150 million, before
Wedbush analyst Robert Driscoll upgrades Replimune Group (NASDAQ:REPL) from Neutral to Outperform
FDA grants Replimune accelerated approval for TUDRIQEV in combination with nivolumab to treat advanc
Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the develop
Analysts upgraded Replimune, Madrigal, BBB Foods, Palantir, and Fomento Economico. See other opinion
Leerink Partners analyst Jonathan Chang upgrades Replimune Group (NASDAQ:REPL) from Market Perfor
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio
FDA advisory panel backed Replimune's RP1 melanoma data ahead of the agency's August 2 decis
US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon sh
Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ:REPL) with a Neutral and raises
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-
Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See wha
AMZN: 13% | Amazon.com shares are trading higher after the company reported better-than-expected Q2
Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pr
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-backs-replimune-skin-cancer
Replimune shares fall after FDA briefing documents questioned RP1 trial data for advanced melanoma a
Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular se
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Cana
Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ:REPL) with a Neutral and raises
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.76) per share which missed the analys
Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D
Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company pioneering the developme
FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy ap
Several stocks, including Optimum Communications Services, surged while Dow fell. Technology, energy